Breast Cancer Research and Treatment **56**: 293, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 56

Akazawa K 113
Akutsu M 79
Alanen KA 169
Aldrich T 59
Ando J 79
Apicella A 239

Bianchi U 239
Biglietto M 239
Bisagni G 125
Boni C 125
Bosma AJ 219
Brown PH 277

Cajander J 105
Capasso I 239
Cartenì G 239
Casibang M 177
Cavanaugh PG 203
Ceci G 125
Cocconi G 125
Collan YU 169
Comella G 239
Comella P 239
Concin N 91
Coombes RC 25
Cooper MR 59
Coy D 177
Cserwenka K 91,145
Curran EM 35

D'Aiuto G 239
D'Aniello R 239
D'Ottavio AM 233
De Lisi V 125
De Lucia L 239
Denny TN 153
Di Blasio B 125
Di Bonito M 239
Dohi K 113
Doody D 25
Dowsett M 25

Eida K 113
Ellmén J 133
Emdin SO 105
English J 25

Fabi A 233
Fenig E 153
Frasci G 239
Fuqua SAW 187

Ganz PA 45
Garcia-Conde J 67
Garufi C 233
Gershanovich M 133
Gillesby BE 253
Gooch JL 1
Gozes Y 177
Gruber DM 145

Hansen RK 187
Hatzell TA 59
Hayes DF 133
Hilsenbeck SG 187
Hirji K 45
Howes A 25
Huang TH-M 35
Huber JC 145

Insa A 67

Jia LB 203
Juntti L 169

Kano Y 79
Kaufmann M 133
Kim H-T 277
Klaver SG 219
Konaga E 113
Kronqvist P 169
Kuopio T 169

Lambrechts AC 219
Lapenta L 239
Laux DE 35
Lemieux P 187
Leodolter S 91
Leyton J 177
Lluch A 67
Lodén M 105
Lubahn DB 35
Lundberg G 105

Maeda M 113
Maehara Y 113
Maiorino L 239
Maloof P 153
Martinez-Agullo A 67
Marugan I 67
Miall S 25
Mildner M 145
Milella M 233
Monden Y 113
Moody TW 177
Morandi P 125
Munoz-Medellin D 277

Nagy A 267
Nevalainen TJ 169
Nicolson GL 203
Nielsen NH 105
Nisticò C 233
Noda S 113
Nomura Y 113

Oesterreich S 187
Ogawa M 113
Ostrowski J 277

Parra I 187
Paskett E 59
Passalacqua R 125
Perebolte L 219
Petersen L 45
Piccolo S 239
Pisegna J 177
Prosper F 67
Purdom S 177
Pyrhönen S 133

Reczek P 277
Ricketts TC 59
Rodenhuis S 219

Sator MO 145
Savoldi L 125
Schally AV 267
Schiebel I 91
Schneeberger C 91,145
Sedlak J 91
Shiba E 11
Shimozuma K 45
Stein D 153
Sugimachi K 113
Sugimoto T 11
Suzuki K 79
Szepeshazi K 267

Takai S 11
Tanaka N 113
Terzoli E 233
Thomas R 239
Toge T 113
Tominaga T 133
Tong D 91
Top B 219
Tropman SE 59
Tschugguel W 145
Tsunoda S 79

Unfried G 145

Vaccaro A 233
Van Den Berg CL 1
van't Veer LJ 219
Vuorinen J 133

Waldhoer T 145
Wang H 153
Wang Q 153
Watanabe T 11
Welshons WV 35
Weninger W 145
Wieder R 153

Yahalom J 153
Yang L 277
Yee D 1

Zacharewski TR 253
Zadro A 125
Zeillinger R 91
Zia F 177
Zou YY 203

Breast Cancer Research and Treatment **56**: 295-297, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 56

adriamycin
see doxorubicin
androgen receptor
possible mediator of MPA down-regulation of PTHrP in bone metastasis 11-23
antiestrogens
meta-analysis of tamoxifen vs. toremifene trials 133-143
AP-1 transcription factors
inhibition by growth-suppressing retinoids without RAR-dependent gene activation 277-291
apoptosis
chemotherapy-induced, IGF-I protection 1-10
promoted by bFGF down-regulation of Bcl-2 in MCF-7 cells 153-167
aromatase inhibitors
vorozole more effective than formestane in suppressing estrogen, ± GnRH agonist 25-34

Bcl-2
down-regulation by bFGF in MCF-7 cells 153-167
bone metastasis
PTHrP down-regulated by MPA, not estrogens 11-23

cell cycle
markers of G1-S defects and breast cancer survival 105-112
chemoendocrine therapy
postoperative combinations of mitomycin C, tamoxifen, and UFT (tegafur+uracil) 113-124
chemotherapy
doxorubicin derivative targeted by LH-RH conjugation — activity in mouse MXT tumors 267-276
schedule-dependent interactions between vinorelbine and paclitaxel 79-90
weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer 239-252
weekly epirubicin plus lonidamine in advanced breast cancer 233-237
circulating breast cancer cells
false-positives by 3 detection methods based on cytokeratin 19 219-231
cisplatin
combinations in neoadjuvant treatment of Stage III and locally recurrent disease 125-132
cisplatin *continued*
weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer 239-252
combination chemotherapy
in vitro data favoring simultaneous over sequential vinorelbine and paclitaxel 79-90
cyclins
markers of G1-S defects and breast cancer survival 105-112
cytokeratin 19
false-positives by 3 detection methods for circulating breast cancer cells 219-231

detection
of circulating tumor cells — cytokeratin 19 an unsuitable target 219-231
doxorubicin
derivative targeted by LH-RH conjugation — activity in mouse MXT tumors 267-276
IGF-I rescue via anti-apoptotic effect on PI-3K 1-10
resistance by hsp27 overexpression, lowering apoptosis and topoisomerase II 187-196

endocrine therapy
meta-analysis of tamoxifen vs. toremifene trials 133-143
vorozole more effective than formestane in suppressing estrogen, ± GnRH agonist 25-34
epirubicin
weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer 239-252
weekly epirubicin plus lonidamine in advanced breast cancer 233-237
estrogen receptor
and absence of PAI-1 marks non-invasive breast cancer cell lines 91-97
association with PSA in prognosis of premenopausal patients 169-176

fibroblast growth factors (FGFs)
bFGF promotes apoptosis in MCF-7 cells by down-regulating Bcl-2 153-167
formestane
less effective than vorozole in suppressing estrogen, ± GnRH agonist 25-34

gene methylation
see methylation
goserelin
with aromatase inhibitors in suppressing estrogen 25-34

hsp27
overexpression inhibits Dox-induced apoptosis and lowers topoisomerase II 187-196

insulin-like growth factors (IGFs)
IGF-I protection from chemotherapy-induced apoptosis 1-10
invasiveness
marked by PAI-1 and absence of ER in breast cancer cell lines 91-97

LH-RH receptors
doxorubicin/LH-RH derivatives in targeted therapy of mouse MXT tumors 267-276
lonidamine
weekly epirubicin plus lonidamine in advanced breast cancer 233-237

MCF-7 human breast cancer cells
bFGF promotes apoptosis by down-regulating Bcl-2 153-167
medroxyprogesterone acetate (MPA)
down-regulation of PTHrP and bone metastasis 11-23
metastasis
enhanced by transferrin receptor overexpression in rat mammary tumor cell line 203-219
possible inhibition by inducible-form nitric oxide synthase 145-151
methylation
hypermethylation of WT1 tumor suppressor gene CpG islands in breast cancer cells 35-43
mitogen-associated protein kinase (MAPK)
required for IGF-I rescue from paclitaxel-induced cell death 1-10
mitomycin C
postoperative combinations with tamoxifen, UFT (tegafur+uracil) 113-124
MTLn2 rat mammary tumor cell line
metastasis enhanced by transferrin receptor overexpression 203-219
MXT mouse mammary tumors
doxorubicin/LH-RH derivatives in targeted therapy 267-276

neoadjuvant chemotherapy
cisplatin combinations in treatment of Stage III and locally recurrent disease 125-132
nitric oxide synthases
inducible form lost in high grade breast cancer 145-151

paclitaxel
IGF-1 rescue via proliferative effect on PI-3K and MAPK 1-10
schedule-dependent interactions with vinorelbine in vitro 79-90
weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer 239-252
PAI-1 (plasminogen activator inhibitor-1)
and absence of ER marks invasive cell lines 91-97
phosphoinositol 3-kinase
in IGF-I rescue from doxorubicin-induced apoptosis 1-10
pituitary adenylate cyclase activating polypeptide
stimulation of cAMP, c-fos, and colony formation inhibited by PACAP(6-38) 177-186
predictive factors
for antiestrogen responses 133-143
primary chemotherapy
see neoadjuvant chemotherapy
prognostic factors
markers of G1-S cell cycle defects 105-112
pS2 by qRT-PCR — association with ER, PgR, small tumor size 253-265
site, nodes, ER, and DFI predict survival from first recurrence 67-78
prostate-specific antigen (PSA)
incidence and (low) prognostic value by immunohistochemistry 169-176
pS2
by qRT-PCR — association with ER, PgR, small tumor size 253-265
psychological distress
quality of life after breast cancer surgery — rehabilitation needs 45-57
PTHrP (parathyroid hormone-related protein)
in bone metastasis — down-regulation by MPA, not estrogens 11-23

quality of life
after breast cancer surgery — rehabilitation needs 45-57

Rb (retinoblastoma protein)
markers of G1-S defects and survival 105-112

rehabilitation
quality of life after breast cancer surgery 45-57
retinoic acid
immortal and malignant breast cells less sensitive than normal cells 277-291
retinoids
growth inhibition by AP-1 suppression without RAR-dependent gene transactivation 277-291
rural breast cancer treatment
lower compliance with national recommendations 59-66

surgery
quality of life independent of type of surgery 45-57
survival from first recurrence
predicted by site, nodes, ER, DFI 67-78

tamoxifen
postoperative combinations with mitomycin C, UFT (tegafur+uracil) 113-124
vs. toremifene — meta-analysis of comparative trials 133-143
taxol
see paclitaxel
tegafur
postoperative combinations with tamoxifen, mitomycin C 113-124
topoisomerase II
lowered by hsp27 overexpression 187-196
toremifene
vs. tamoxifen — meta-analysis of comparative trials 133-143
transferrin receptor
overexpression enhances metastasis of rat mammary tumor cell line 203-217
treatment recommendations
lower compliance in rural communities 59-66
tumor suppressor genes
hypermethylation of WT1 CpG islands in breast cancer cells 35-43

UFT (tegafur plus uracil)
see tegafur

vasoactive intestinal peptide family
PACAP stimulation of cAMP, c-fos, and colony formation inhibited by PACAP(6-38) 177-186
vinorelbine
schedule-dependent interactions with paclitaxel in vitro 79-90
vorozole
more effective than formestane in suppressing estrogen, ± GnRH agonist 25-34